High-dose therapy with autologous marrow or peripheral blood stem cell
(PBSC) rescue has been extensively applied in the treatment of multip
le myeloma (MM) patients during the past 10 years resulting in improve
d event-free and overall survival when compared with standard chemothe
rapy. However, relapses are common and cure is unlikely in the majorit
y of patients. Because both bone marrow and PBSCs are contaminated wit
h myeloma cells it is conceivable that relapse after autotransplantati
on originates at least in part from autografted tumor cells. In this s
tudy, mobilized PBSCs were examined for the presence of myeloma cells
based on immunophenotyping and sensitive polymerase chain reaction (PC
R)-based techniques. In addition, CD34(+) Lin(-) Thy(+) stem cells wer
e purified from mobilized PBSC harvests of 10 MM patients by sequentia
lly using counterflow elutriation centrifugation, treatment with pheny
lalanine methylester, and flow sorting, using 5-parameter gating (prop
idium iodide, forward scatter, side scatter, CD34(+) v Lin(-) and CD34
(+) v Thy(+)). Virtually all mobilized unsorted PBSC preparations cont
ained myeloma cells in sufficient quantities (range, <0.01 to >10%) po
tentially causing a disease relapse. Stem cell purification led to an
overall enrichment by about 50-fold in all 10 patients; approximate to
90% of the final cell population expressed CD34(+) Lin(-) Thy(+) with
no evidence of myeloma cell contamination based on flow cytometric an
alysis of CD38(bright) cells (<0.1%). Quantitative PCR amplification o
f patient-specific complementarity determining region III (CDRIII) DNA
sequences showed depletion of clonal B cells by 2.7 to 7.3 logs, with
the highest log reduction noted in the samples initially containing t
he most tumor cells. Our results show that purification of CD34(+) Lin
(-) Thy(+) cells depletes myeloma cells to undetectable levels from up
to 10% present in unsorted PBSCs, thus offering a tool to investigate
whether MM relapse after autotransplantation can be reduced markedly.
(C) 1995 by The American Society of Hematology.